These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 18714733

  • 21. [Comment from the lipidologic viewpoint].
    Riesen WF.
    Praxis (Bern 1994); 2009 Feb 04; 98(3):125-7. PubMed ID: 19180437
    [No Abstract] [Full Text] [Related]

  • 22. Statin pharmacology may have important clinical implications.
    Am J Manag Care; 2002 Jul 04; Suppl Symposium Reporter():2, 5. PubMed ID: 12608150
    [No Abstract] [Full Text] [Related]

  • 23. Primary prevention cardiovascular disease: better than drugs.
    Pippin JJ.
    Arch Intern Med; 2010 Nov 08; 170(20):1860-1; author reply 1861. PubMed ID: 21059984
    [No Abstract] [Full Text] [Related]

  • 24. [How far the rates of cholesterol have to be lowered in primary prevention?].
    Rodondi N.
    Rev Med Suisse; 2010 Mar 10; 6(239):483-4. PubMed ID: 20373693
    [No Abstract] [Full Text] [Related]

  • 25. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF.
    Angiology; 2010 Mar 10; 59(6):661-3. PubMed ID: 18796445
    [No Abstract] [Full Text] [Related]

  • 26. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
    Olsson AG.
    Lakartidningen; 2010 Mar 10; 108(22-23):1240-3. PubMed ID: 21786498
    [No Abstract] [Full Text] [Related]

  • 27. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    Arterioscler Thromb Vasc Biol; 2004 Aug 10; 24(8):e149-61. PubMed ID: 15297292
    [Abstract] [Full Text] [Related]

  • 28. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    J Am Coll Cardiol; 2004 Aug 04; 44(3):720-32. PubMed ID: 15358046
    [Abstract] [Full Text] [Related]

  • 29. In brief: Zetia and Vytorin: the ENHANCE study.
    Med Lett Drugs Ther; 2008 Jan 28; 50(1278):5. PubMed ID: 18219263
    [No Abstract] [Full Text] [Related]

  • 30. Researchers still seek clinical benefit in raising levels of good cholesterol.
    Mitka M.
    JAMA; 2012 Jan 04; 307(1):21-2. PubMed ID: 22215155
    [No Abstract] [Full Text] [Related]

  • 31. [Primary and secondary prevention of coronary disease by statins].
    Ferrières J.
    Ann Cardiol Angeiol (Paris); 1999 Feb 04; 48(2):128-36. PubMed ID: 12555337
    [Abstract] [Full Text] [Related]

  • 32. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
    MMW Fortschr Med; 2005 Aug 18; 147(33-34):51. PubMed ID: 16138641
    [No Abstract] [Full Text] [Related]

  • 33. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P.
    Am J Manag Care; 2009 Mar 18; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.